Liraglutide (Victoza, Saxenda) Liraglutide, marketed as Victoza for diabetes and Saxenda for weight management, is a once-daily injection that has been shown to significantly reduce HbA1c levels and body weight
Taken together, these HSF/HSP members differ in both reproductive relevance and evidence strength, with some supported by established spermatogenic roles and others remaining preliminary biomarker or therapeutic candidates (Table 1)
People who have previously run GLP-1 based compounds and noticed post-cycle skin changes, either laxity or reduced firmness compared to their target weight look, are strong candidates for adding GHK-Cu to their next Retatrutide cycle
Individuals under 18, pregnant or nursing individuals, or those with active medical conditions - per the brand's own label caution, physician consultation is recommended before use in these groups
Feeney, M